Overview

CytoSorbents Investor Relations

CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with >270,000 CytoSorb devices sold in 70+ countries to date, and with applications to FDA and Health Canada for DrugSorb-ATR marketing approval under review.

Featured News

CytoSorbents

Press Release

31 Jul '25

CytoSorbents Leads a New Era in Sepsis Treatment

CytoSorbents highlights the vital and evolving role of CytoSorb® in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10th PRINCETON, N.J., July 31, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ... CytoSorbents Leads a New Era in Sepsis Treatment

29 Jul '25

CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

PRINCETON, N.J., July 29, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2025 financial results and recent business highlights after the market close on Thursday, August 7, 2025. CytoSorbents’ management will host a ... CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

02 Jul '25

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

PRINCETON, N.J., July 2, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada. DrugSorb-ATR is an FDA-designated Breakthrough Device designed ... CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

24 Jun '25

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

PRINCETON, N.J., June 24, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR ... CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

View All News